← Patent-cliff monitor small molecule TUKYSA TUCATINIB
Loss of exclusivity April 2038 latest FDA-listed patent expiry
Company Seagen → See this company's full patent-cliff portfolio Drug detail Brand name TUKYSA Active ingredient TUCATINIB Strength 150MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2020 Marketing status RX
Listed patents Patent Expires Type 11207324 April 2038 use U-3783 11666572 April 2038 use U-3783 12048698 April 2038 use U-3783 8648087 April 2034 substance, product 11504370 March 2033 use U-2788 9457093 October 2032 product 9693989 May 2027 product
Regulatory exclusivity Code Expires ODE-422 January 2030 ODE-309 April 2027 I-906 January 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.